Merck’s Oxytrol Could Go From Rx Also-Ran To OTC Star – Analysts
This article was originally published in The Pink Sheet Daily
Executive Summary
Watson’s Oxytrol currently has just a 1% share of the overactive bladder drug market, but Kline and Kalorama analysts see sizable potential should it switch OTC.
You may also be interested in...
Merck Seeks Oxytrol Switch For Women As First Overactive Bladder OTC
Merck will present to FDA’s Nonprescription Drugs Advisory Committee Nov. 9 in support of switching Watson’s Oxytrol as a female-specific OTC.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.